Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Avastin

Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy

DRUG

Tarceva

Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy

RADIATION

Radiation Therapy

Radiation to the pancreas Monday through Friday for 28 treatments

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER